Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Director Sells $4,751,000.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) Director Daniel Janney sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $95.02, for a total transaction of $4,751,000.00. Following the sale, the director now directly owns 157,362 shares of the company’s stock, valued at approximately $14,952,537.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Daniel Janney also recently made the following trade(s):

• On Tuesday, May 9th, Daniel Janney sold 17,100 shares of Krystal Biotech stock. The stock was sold at an average price of $90.74, for a total transaction of $1,551,654.00.
• On Wednesday, April 19th, Daniel Janney sold 7,900 shares of Krystal Biotech stock. The stock was sold at an average price of $90.32, for a total transaction of $713,528.00.

Krystal Biotech Trading Down 1.0 %

Shares of Krystal Biotech stock opened at $117.39 on Friday. The company’s 50-day moving average price is $86.67 and its two-hundred day moving average price is $81.02. Krystal Biotech, Inc. has a 52 week low of $49.17 and a 52 week high of $123.84. The stock has a market cap of $3.03 billion, a PE ratio of -22.23 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last issued its quarterly earnings results on Monday, February 27th. The company reported ($1.25) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.01. On average, equities analysts predict that Krystal Biotech, Inc. will post -5.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on KRYS shares. HC Wainwright raised their price target on shares of Krystal Biotech from $119.00 to $139.00 in a research report on Monday. William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a report on Wednesday, March 22nd. Guggenheim lifted their price objective on shares of Krystal Biotech from $101.00 to $130.00 in a report on Monday. Stifel Nicolaus lifted their price objective on shares of Krystal Biotech from $102.00 to $145.00 in a report on Wednesday. Finally, The Goldman Sachs Group raised shares of Krystal Biotech from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $79.00 to $124.00 in a report on Tuesday, February 28th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $134.00.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently bought and sold shares of the business. Almanack Investment Partners LLC. purchased a new position in Krystal Biotech in the 3rd quarter worth about $52,000. Allspring Global Investments Holdings LLC increased its stake in Krystal Biotech by 260.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 981 shares of the company’s stock worth $68,000 after purchasing an additional 709 shares in the last quarter. Great West Life Assurance Co. Can increased its stake in Krystal Biotech by 51.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 1,013 shares of the company’s stock worth $72,000 after purchasing an additional 346 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Krystal Biotech by 148.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 956 shares of the company’s stock worth $77,000 after purchasing an additional 571 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Krystal Biotech in the 1st quarter worth about $104,000. 80.80% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

(Get Rating)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.